系统性硬化症中的便失禁:一个叙述性回顾
Mickaël Martin1, Van-Minh Nguyen2, Mathieu Puyade3
1Service de médecine interne, centre hospitalier universitaire de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France; Inserm U1313, université de Poitiers, Poitiers, France.
La Revue de medecine interne
|February 27, 2026
概括
便失禁 (FI) 在全身性硬化症 (SSc) 患者中常见且严重,影响生活质量. 建议对这种经常被忽视的疾病进行定期查和多学科管理,包括改变生活方式和生物反.
科学领域:
- 胃肠病学 胃肠病学
- 类风湿病学 类风湿病学
- 神经学 神经学
背景情况:
- 便失禁 (FI) 显著影响生活质量,但在全身性硬化症 (SSc) 中经常被忽视.
- 在SSc中的FI病理生理学是复杂的,涉及血管病变,纤维化和潜在的自身免疫神经病变.
- 在SSc中FI的患病率是一般人群的5-6倍,严重病例在15%中.
研究的目的:
- 为了突出系统性硬化症患者便失禁的诊断不足.
- 审查复杂的病理生理学和SSc.中FI的相关因素.
- 推查,诊断方法和管理策略的FI在SSc.
主要方法:
- 对系统性硬化症中便失禁现有文献的综述.
- 讨论诊断工具,包括问卷,数字直肠检查,神经评估,内镜检查和直肠测量.
- 多学科管理策略的概要.
主要成果:
- 与一般人群相比,FI在SSc患者中明显更为普遍,并且往往更为严重.
- 相关疾病包括腹,小肠细菌过度生长,便秘,尿失禁和特定的自身抗体.
- 目前的管理符合一般人口的指导方针,强调生活方式的修改和生物反治疗.
结论:
- 在所有全身性硬化症患者中,定期查便失禁至关重要.
- 综合饮食,生活方式变化,生物反和向治疗的多学科方法对于有效的管理至关重要.
- 对于神经刺激和便微生物群移植等新的治疗方法,需要进一步的研究.
相关概念视频
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
999
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
999
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
941
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
941
01:17Irritable Bowel Syndrome I: Introduction
1.3K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.3K
01:21Inflammatory Bowel Disease V: Surgical Management
780
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
780
01:17Chronic Bowel Disorders: Introduction
855
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
855
01:21Drugs for Treatment of Constipation-Predominant IBS
1.0K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K